Non-steroidal anti-inflammatory drug use and cervical cancer risk: A case-control study using the Clinical Practice Research Datalink

Cancer Epidemiology

Volumn 37, Issue 6, 2013, Pages 897-904

  Wilson, J C ^a   O'Rorke, M A ^a   Cooper, J A ^a   Murray, L J ^a   Hughes, C M ^a   Gormley, G J ^a   Anderson, L A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Anti inflammatory agents; Aspirin; Non steroidal; Uterine cervical neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DATA BASE; DRUG MEGADOSE; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SMOKING; UNITED KINGDOM; UTERINE CERVIX CANCER;

ANTI-INFLAMMATORY AGENTS; ASPIRIN; NON-STEROIDAL; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84888307464     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.08.010     Document Type: Article

References (49)

1. Cancer Research UK Cervical cancer 2012, CRUK, Available from http://www.cancerresearchuk.org/cancer-info/cancer.
2. Bosch F.X., Manos M.M., Munoz N., Sherman M.E., Jansen A., Peto J., et al. Prevalence of HPV DNA in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87:796-802.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):9-12.
4. Pisani P., Parkin M., Munoz N., Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997, 6:387-400.
5. Muñoz N., Bosch X.F., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
6. Ferenczy A., Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002, 3(1):6-11.
7. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: ameta-analysis update. Int J Cancer 2007, 121(3):621-632.
8. Snijders P.J., Steenbergen R.D., Heideman D.A., Meijer C.J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006, 208(2):152-164.
9. Reiter P.L., Katz M.L., Ferketich A.K., Ruffin M.T., Paskett E.D. Measuring cervical cancer risk: development and validation of the CARE Risky Sexual Behavior Index. Cancer Causes Control 2009, 20(10):1865-1871.
10. International Collaboration of Studies of Cervical Cancer Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006, 118:1481-1495.
11. Franco E.L., Spence A.R. Commentary: smoking and human papillomavirus infection: the pursuit of credibility for an epidemiologic association. Int J Epidemiol 2008, 37(3):547-548.
12. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P., Beral V., Berrington de González A., Colin D., Franceschi S., et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007, 370(9599):1609-1621.
13. Muñoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093-1101.
14. Muñoz N., Castellsagué X., de González A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006, 24(3). S3/1-10.
15. Burchell A.N., Winer R.L., de Sanjosé S., Franco E.L. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, S3. S3/52-61.
16. Boccardo E., Lepique A.P., Villa L.L. The role of inflammation in HPV carcinogenesis. Carcinogenesis 2010, 31(11):1905-1912.
17. Kim K.Y., Seol J.Y., Jeon G.A., Nam M.J. The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 andcaspase-3 in human cervical cancer cell. Cancer Lett 2003, 189(2):157-166.
18. Yueling W., Hongmin Z., Lin L., Jiangfen W. Effect of aspirin alone or combined with cisplatin on human cervical carcinoma HeLa cells. J Med Coll PLA. 2010, 25(1):11-18.
19. Xiang S., Sun Z., He Q., Yan F., Wang Y., Zhang J. Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells. Med Oncol 2010, 27(2):379-387.
20. Saha B., Adhikary A., Ray P., Saha S., Chakraborty S., Mohanty S., et al. Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells. Oncogene 2012, 31(2):173-186.
21. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001, 7:429-434.
22. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000, 76(3):320-325.
23. Dai Y., Zhang X., Peng Y., Wang Z. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol 2005, 97(1):96-103.
24. Sales K.J., Katz A.A., Davis M., Hinz S., Soeters R.P., Hofmeyr M.D., et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of thecervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 2001, 86(5):2243-2249.
25. Lee J.S., Choi Y.D., Lee J.H., Nam J.H., Choi C., Lee M.C., et al. Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol Oncol 2004, 95(3):523-529.
26. Young J.L., Jazaeri A.A., Darus C.J., Modesitt S.C. Cycloxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 2008, 109:140-145.
27. Friis S., Sørensen H.T., McLaughlin J.K., Johnsen S.P., Blot W.J., Olsen J.H. A population-based study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003, 88:684-688.
28. Sørensen H.T., Friis S., Nørgård B., Mellemkjær L., Blot W.J., McLaughlin J.K., et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692.
29. Wood L., Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004, 27(12):871-881.
30. Jick H., Jick S.S., Derby L.E. Validation of information recorded on general practioner based computerised data resource in the United Kingdom. BMJ. 1991, 302(6779):766-768.
31. Tate A.R., Martin A.G.R., Murray-Thomas T., Anderson S.R., Cassell J.A. Determining the date of diagnosis--is it a simple matter? The impact of different approaches to dating diagnosis on estimates of delayed care for ovarian cancer in UK primary care. BMC Medical Research Methodology 2009, 9:42. Available from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2711114&tool=pmcentrez&rendertype=Abstract [cited 31.07.13].
32. Huberman M., Langholz B. Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol 1999, 150:1340-1345.
33. Adami H.O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women recieving hormone replacement therapy. Int J Cancer 1989, 44(5):833-839.
34. Parazzini F., La Vecchia C., Negri E., Franceschi S., Moroni S., Chatenoud L., et al. Case-control study of oestrogen replacement therapy and risk of cervical cancer. BMJ 1997, 315(7100):85-88.
35. Vane J.R., Flower R.J., Blotting R.M. History of aspirin and its mechanism of action. Stroke 1990, 21(12 Suppl. 4):12-23.
36. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
37. Zhang X., Morham S.G., Langenbach R., Young D.A. Malignant transformation and antineoplastic actions of non-steroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroplasts. J Exp Med 1999, 4:451-459.
38. Hwang D.H., Fung V., Dannenberg A.J. National Cancer Institute workshop on chemopreventative properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and independent mechanisims. Neoplasia 2002, 4(2):91-97.
39. Powell M.A., Pfeifer J.D., Buttin B.S., Gibb R.K., Luck M.B., Rader J.S. A pilot study of celecoxib in the treatment of patients with cervical and vaginal intraepithelial neoplasia. Proc Am Soc Clin Oncol. 2003, 22. (abstract 1830).
40. Farley J.H., Truong V., Goo E., Uyehara C., Belnap C., Larsen W.I. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecol Oncol 2006, 103(2):425-430.
41. Hefler L.A., Grimm C., Speiser P., Sliutz G., Reinthaller A. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol 2006, 125(2):251-254.
42. Gandamihardja S., Wirakusumah F.F., Shahib N., Sastramihardja H.S., Sastramihardja H.S., Farid Aziz M. Role of cyclooxygenase on cervical cancer growth. MKB 2010, 42(4):169-174.
43. Proprietary Association of Great Britain Annual review 2012 2013, Available from http://www.pagb.co.uk/publications/annualreview.html.
44. Yang Y.-X., Hennessy S., Propert K., Hwang W.-T., Sarkar M., Lewis J.D. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiology and Drug Safety 2008, 17(9):869-876. Available from http://www.ncbi.nlm.nih.gov/pubmed/18412290 [cited 02.08.13].
45. Yood M.U., Campbell U.B., Rothman K.J., Jick S.S., Lang J., Wells K.E., et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiology and Drug Safety 2007, 16(9):961-968. Available from http://www.ncbi.nlm.nih.gov/pubmed/17654746 [cited 02.08.13].
46. Hawkey C.J., Cullen D.J., Pearson G., Holmes S., Doherty M., Wilson J.V., et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000, 14(2):177-185.
47. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012, 125(9):882-887.
48. Donders A.R., van der Heijden G.J., Stijnen T., Moons K.G. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006, 59(10):1087-1091.
49. Family Planning Association Sexually transmitted infections 2010, Family Planning Association, London, Factsheet. Available from http://www.fpa.org.uk/media/uploads/professionals/factsheets-non-printing/sexually-transmitted-infections-factsheet-november-2010.pdf.